key: cord-0742300-a9rte0z0
authors: Westhölter, Dirk; Taube, Christian
title: SARS-CoV-2 outbreak in a long-term care facility after vaccination with BNT162b2
date: 2021-04-07
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab299
sha: 32a78a7282538828458020fee85ef658312743ce
doc_id: 742300
cord_uid: a9rte0z0

nan

A c c e p t e d M a n u s c r i p t Dear Editor:

The recently approved BNT162b2 vaccine has demonstrated a 95% protection against Covid-19 1 . It has been proposed to delay the boosting dose of BNT162b2 in order to provide more individuals with at least single doses of the vaccine. The responsible UK authorities approved this policy and thereby initiated a controversial debate 2,3 . Several arguments against this policy have recently been presented in this journal 4 . There is missing evidence whether a single dose regimen is sufficient to terminate transmission chains. Here we report a SARS-CoV-2 outbreak after application of the first dose of BNT162b2 vaccine in an elderly care home in North-Rhine Westfalia, Germany. This Our analysis of a SARS-CoV-2 outbreak revealed a vulnerable phase after administration of the first dose of BNT162b2 in a long-term care facility. Indeed, the measured low mean CT values and high mortality observed in this population were consistent with "natural" Covid-1919 disease rather than vaccine-attenuated. Preprint data from Israel demonstrate a 51% effectiveness of a single BNT162b2 dose in reducing SARS-CoV-2 infections 13-24 days after vaccination. However, clinical outcome parameters of the detected infections were not analyzed 5 . Here we report that a single dose of BNT162b2 did not prevent symptomatic and fatal outcomes of SARS-CoV-2 infections in this high-risk population up to 23 days after the initial vaccination indicating an incomplete protection against severe Covid-19 for that period.

The authors have no potential conflicts.

Safety and Efficacy of the BNT162b2 mRNA Covid-19

COVID-19 vaccination -for immediate action

Covid-19 vaccines: to delay or not to delay second doses

The case against delaying SARS-CoV-2 mRNA vaccine boosting doses

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. medRxiv

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t